You are here:

budesonide 2mg Rectal Foam (Budenofalk)


Following an abbreviated submission

budesonide rectal foam (Budenofalk®) is accepted for use within NHS Scotland for the treatment of active ulcerative colitis that is limited to the rectum and the sigmoid colon.

It should be used in patients for whom rectally administered budesonide is an appropriate choice of treatment. It costs less than equivalent doses of the other rectal formulation of budesonide.

Drug Details

Drug Name: budesonide 2mg Rectal Foam (Budenofalk)
SMC Drug ID: 409/07
Manufacturer: Dr Falk Pharma UK
Indication: Ulcerative colitis
BNF Category:
Sub Category: 1.5 Chronic bowel disorders
Submission Type: Abbreviated Submission
Status: Accepted
Date Advice Published: 8 October 2007